genome-wide association studies candidate gene to dual modifier of nonalcoholic steatohepatitis and atherosclerosis

Clicks: 280
ID: 202941
2016
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #11 of 42 articles by views in journal of nuclear materials

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Nonalcoholic steatohepatitis is a common disease involving chronic accumulation of fat and inflammation in the liver, often leading to advanced fibrosis, cirrhosis, and cancer. It is known that nonalcoholic steatohepatitis shares many features with atherosclerosis; however, there are still no effective therapeutics. In a recent study published in Nature, investigators demonstrated that mice lacking a high-density lipoprotein–associated gene were surprisingly protected from both steatohepatitis and atherosclerosis through the stabilization of the liver X receptor. This work reveals a timely candidate target for 2 highly prevalent cardiovascular diseases.
Reference Key
phd2016jacc:genome-wide Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Clint L. Miller, PhD;Nicholas J. Leeper, MD
Journal journal of nuclear materials
Year 2016
DOI
10.1016/j.jacbts.2016.09.006
URL
http://www.sciencedirect.com/science/article/pii/S2452302X16301620
Keywords
atherosclerosis fatty liver genome-wide association studies

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.